Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $60

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $21 to $60.